HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy.

AuthorsNaseema Gangat, Natasha Szuber, Hassan Alkhateeb, Aref Al-Kali, Animesh Pardanani, Ayalew Tefferi
JournalBlood (Blood) Vol. 138 Issue 26 Pg. 2886-2889 (12 30 2021) ISSN: 1528-0020 [Electronic] United States
PMID34653249 (Publication Type: Letter)
Chemical References
  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin
  • dapagliflozin
  • JAK2 protein, human
  • Janus Kinase 2
  • empagliflozin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Benzhydryl Compounds (adverse effects, therapeutic use)
  • Canagliflozin (adverse effects, therapeutic use)
  • Female
  • Glucosides (adverse effects, therapeutic use)
  • Humans
  • Janus Kinase 2 (genetics)
  • Male
  • Middle Aged
  • Polycythemia (chemically induced, genetics)
  • Sodium-Glucose Transporter 2 Inhibitors (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: